uniQure N.V. Presents AMT-130 Clinical Trial Update (Reg FD 8-K)

What Happened

• On September 29, 2026, uniQure N.V. announced and publicly presented an update on its ongoing clinical trials of AMT‑130 and issued a press release summarizing that presentation.
• The company furnished the presentation and the press release as Exhibits 99.1 and 99.2 to its Form 8‑K under Item 7.01 (Regulation FD disclosure).

Key Details

• Date of disclosure: September 29, 2026.
• Filing item: Item 7.01 — Regulation FD Disclosure (presentation and press release furnished).
• Exhibits filed: 99.1 (Presentation) and 99.2 (Press Release); Inline XBRL cover page included as Exhibit 104.
• The materials were furnished with the Form 8‑K and incorporated into the filing.

Why It Matters

• Clinical-trial updates can contain information about timing, safety, or efficacy that investors use to assess program progress and potential value of the AMT‑130 program.
• This Form 8‑K is a Regulation FD disclosure, meaning uniQure aimed to broadly share the information at the same time with the public and investors; review Exhibits 99.1/99.2 for the specific data or timelines disclosed.
• The filing does not report financial results or executive changes; it primarily provides the presentation and press release for investor review.